CHRS Insider Trading Activity and SEC Form 4 Filings
CHRS insider trading summary
No open-market insider purchases or sales of Coherus BioSciences, Inc. (CHRS) have been reported on SEC Form 4 in the past 12 months.
Latest CHRS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 23, 2025 | Mats Wahlstrom | Insider | Sell | $74K (99,988 @ $0.74) |
| Nov 22, 2023 | Dennis M Lanfear | President & CEO | Sell | $450K (223,100 @ $2.02) |
| Oct 15, 2021 | McDavid Stilwell | Chief Financial Officer | Sell | $59K (3,507 @ $16.80) |
| Sep 29, 2021 | James Healy | Director | Sell | $4.6M (286,076 @ $16.12) |
| Sep 28, 2021 | James Healy | Director | Sell | $830K (48,329 @ $17.17) |
| Sep 27, 2021 | James Healy | Director | Sell | $1.8M (100,150 @ $18.06) |
| Jun 9, 2021 | McDavid Stilwell | Chief Financial Officer | Buy | $50K (3,700 @ $13.42) |
| Jun 8, 2021 | Dennis M Lanfear | President & CEO | Sell | $421K (31,054 @ $13.56) |
| Mar 9, 2021 | Vladimir Vexler | Chief Scientific Officer | Sell | $1.9M (114,240 @ $16.25) |
| Mar 5, 2021 | Vincent R Anicetti | Chief Operating Officer | Sell | $314K (20,312 @ $15.46) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.